- Home
- PGY vs GLPG Comparison
PGY vs GLPG Comparison
Compare PGY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- GLPG
- Stock Information
- Founded
- PGY 2016
- GLPG 1999
- Country
- PGY United States
- GLPG Belgium
- Employees
- PGY N/A
- GLPG N/A
- Industry
- PGY Finance: Consumer Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- GLPG Health Care
- Exchange
- PGY Nasdaq
- GLPG Nasdaq
- Market Cap
- PGY 2.4B
- GLPG 2.1B
- IPO Year
- PGY N/A
- GLPG 2005
- Fundamental
- Price
- PGY $33.30
- GLPG $32.47
- Analyst Decision
- PGY Strong Buy
- GLPG Sell
- Analyst Count
- PGY 9
- GLPG 4
- Target Price
- PGY $34.44
- GLPG $25.33
- AVG Volume (30 Days)
- PGY 4.0M
- GLPG 440.5K
- Earning Date
- PGY 08-07-2025
- GLPG 07-23-2025
- Dividend Yield
- PGY N/A
- GLPG N/A
- EPS Growth
- PGY N/A
- GLPG N/A
- EPS
- PGY N/A
- GLPG N/A
- Revenue
- PGY $1,153,015,000.00
- GLPG $323,674,692.00
- Revenue This Year
- PGY $23.03
- GLPG N/A
- Revenue Next Year
- PGY $15.51
- GLPG N/A
- P/E Ratio
- PGY N/A
- GLPG N/A
- Revenue Growth
- PGY 24.59
- GLPG 5.43
- 52 Week Low
- PGY $8.20
- GLPG $22.36
- 52 Week High
- PGY $41.48
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- PGY 63.07
- GLPG 55.82
- Support Level
- PGY $31.24
- GLPG $31.30
- Resistance Level
- PGY $34.36
- GLPG $32.91
- Average True Range (ATR)
- PGY 3.29
- GLPG 0.80
- MACD
- PGY -0.11
- GLPG -0.23
- Stochastic Oscillator
- PGY 40.85
- GLPG 45.70
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.